drugset / Trial / NCT00073762
Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive Disorder
RandomizedParallel-groupDouble-blindTreatment
Summary
Primary Objective: To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo. Secondary Objective: To assess the response of subjects receiving DVS-233 SR for the clinical global evaluation, functionality, general wellbeing, pain, and absence of symptoms (Hamilton Psychiatric Rating Scale for Depression, 17-item \[HAM-D17\] less than or equal to 7) versus those subjects receiving placebo.
Timeline
- Start
- —
- Primary completion
- 2004-09
- Completion
- 2004-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DVS-233 SR | Unknown | 200 mg | — |
| Subject | DVS-233 SR | Unknown | 400 mg | — |